Australia markets closed

Bionomics Limited (BNO.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0300+0.0010 (+3.45%)
At close: 03:36PM AEDT
Full screen
Previous close0.0290
Open0.0300
Bid0.0290 x 2640300
Ask0.0310 x 16362900
Day's range0.0300 - 0.0310
52-week range0.0280 - 0.0980
Volume646,830
Avg. volume674,160
Market cap40.6M
Beta (5Y monthly)2.37
PE ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings date21 Feb 2023 - 27 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est23.00
  • GlobeNewswire

    Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

    BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to PlaceboBNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior ExperienceCompany is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024 ADELAIDE, Australia, Dec. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (B

  • GlobeNewswire

    Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

    Experienced biotech executive to lead the next phase of growthADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has appointed Spyridon “Spyros” Papapetropoulos, M.D. as

  • GlobeNewswire

    Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

    ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders, today announced it will present data on the development of an oral tablet formulation of BNC210 for the treatment of Social Anxiety Disorder (SAD) and data on the pharmacometr